Pharmicell Co (A005690) Q4 2025 earnings summary

Executive summary

• Revenue surged 75.9% year-over-year to KRW 114.1 billion, driven by strong growth in the Bio Chemical segment and increased sales of AI accelerator materials and nucleosides.

• Operating income rose sharply to KRW 34.3 billion, with net income reaching KRW 40.3 billion, reflecting improved profitability and cost control.

• The Bio Medical segment remains in deficit due to ongoing R&D, while the Bio Chemical segment posted robust profits.

• Major investments include the construction of a new Ulsan plant to meet demand for advanced materials and pharmaceutical ingredients.

Financial highlights

• Revenue: KRW 114.1 billion (up 75.9% YoY); Operating income: KRW 34.3 billion (up 636.8% YoY); Net income: KRW 40.3 billion (up 536.4% YoY).

• Gross margin improved to 44.4% from 32.9% YoY.

• Cash and cash equivalents at year-end: KRW 28.9 billion, up from KRW 8.3 billion.

• Total assets increased 58.3% to KRW 157.2 billion; equity rose 43.3% to KRW 123.9 billion.

• Dividend per share proposed at KRW 50 (pending AGM approval).

Outlook and guidance

• Anticipates further growth as the new Ulsan plant comes online and demand for AI and pharmaceutical materials rises.

• Expects continued R&D investment in stem cell therapies, with potential for future commercialization.